We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4188:TSEMitsubishi Chemical Group Corporation Analysis

Data as of 2026-06-11 - not real-time

¥1,036.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Mitsubishi Chemical Group trades at ¥1,036, comfortably above the 20‑day SMA (¥1,060.8) but still below the 50‑day SMA (¥992.9) and 200‑day SMA (¥937), signalling a short‑term bullish bias within a longer‑term uptrend. Technical indicators are mixed: RSI sits at a neutral 49.8, while the MACD histogram is negative (‑11.3) and the signal line is bearish, suggesting possible near‑term downside pressure. Fundamentally, revenue fell 10% YoY, operating margin is –8.4% and trailing EPS is negative (‑¥60.46), yet forward EPS is projected positive (¥91.18) with a forward P/E of 11.36, indicating an expected earnings rebound. The stock offers a 3.14% dividend yield, but a payout ratio of 123% raises concerns about sustainability. Balance‑sheet metrics show ample cash (¥621B) offset by high debt (¥1,890B) and a debt‑to‑equity of 78, highlighting leverage risk. Recent earnings‑call commentary noted a 2% dip in core operating income and a 79% plunge in operating income due to non‑recurring items, underscoring earnings volatility. The market sentiment is extremely greedy (Fear‑Greed Index 83.4) and the price sits near the support level of ¥985.9, with resistance at ¥1,163, while volatility remains elevated at ~45% over 30 days.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD signal and decreasing volume
  • Recent earnings pressure and negative trailing EPS
  • Proximity to support level at ¥985.9

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Forward EPS outlook and modest forward P/E of 11.36
  • Undervalued price relative to DCF fair value (+12% upside)
  • Low beta (0.49) indicating limited market volatility

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Cheap price‑to‑book (0.80) and potential balance‑sheet deleveraging
  • Expected earnings recovery reflected in forward EPS
  • Attractive dividend yield if payout ratio improves

Key Metrics & Analysis

Financial Health

Revenue Growth-10.10%
Profit Margin0.32%
P/E Ratio11.4
ROE-0.70%
ROA0.34%
Debt/Equity78.29
P/B Ratio0.8
Op. Cash Flow¥436.3B
Free Cash Flow¥112.5B

Technical Analysis

TrendBullish
RSI49.8
Support¥985.90
Resistance¥1,163.00
MA 20¥1,060.80
MA 50¥992.86
MA 200¥936.98
MACDBearish
VolumeDecreasing
Fear & Greed Index83.38

Valuation

Fair Value¥149.95
Target Price¥1,037.27
Upside/Downside0.12%
GradeUndervalued
TypeValue
Dividend Yield3.14%

Risk Assessment

Beta0.49
Volatility44.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.